Thelansis

  Soft tissue sarcomas (STS), aggressive mesenchymal-origin tumors, represent 1% of all adult malignancies, with the World Health Organization recognizing over 50 distinct histological subtypes. Currently, the primary treatment strategy for localized STS involves surgery, optionally supplemented with perioperative chemotherapy. For patients with advanced or metastatic STS, the first-line treatment typically consists of palliative anthracycline-based chemotherapy administered either alone or in combination with ifosfamide. This applies to most STS subtypes. STS is known for their aggressive nature and propensity to infiltrate deep tissues. They exhibit a high recurrence rate of 35%, and in 16% of all cases, metastasis is already present at the time of diagnosis, predominantly affecting the lungs. The Overall Survival (OS) for patients with advanced metastatic STS is approximately 12 months. However, recent studies involving newer drugs have extended OS to 18 months. Interestingly,...